Basic Information
-
Targeting strategy
-
Gene targeting strategy for B-hCD89 mice. Human CD89 CDS was inserted into Rosa26 locus with human CD11b promoter in B-hCD89 mice.
-
mRNA expression analysis
-
Strain specific analysis of CD89 gene expression in wild type (WT) mice and B-hCD89 mice by RT-PCR. Human CD89 mRNA was detectable only in splenocytes of homozygous B-hCD89 mice (H/H) but not WT mice (+/+).
-
Protein expression analysis
-
Protein expression analysis in NK cells
Strain specific CD89 expression analysis in homozygous B-hCD89 mice by flow cytometry. Spleen, bone marrow and blood were collected from wild type (WT) mice (+/+) and homozygous B-hCD89 mice (H/H), and analyzed by flow cytometry with species-specific anti-CD89 antibody. Human CD89 was exclusively detectable in NK cells of homozygous B-hCD89 mice (H/H).
Protein expression analysis in CD11b+ cells
Strain specific CD89 expression analysis in homozygous B-hCD89 mice by flow cytometry. Spleen, bone marrow and blood were collected from wild type (WT) mice (+/+) and homozygous B-hCD89 mice (H/H), and analyzed by flow cytometry with species-specific anti-CD89 antibody. Human CD89 was exclusively detectable in CD11b+ cells of homozygous B-hCD89 mice (H/H).
-
Analysis of blood and urine
-
Blood and urine analysis: Four 48-weeks-old male B-hCD89 mice(H/H) and C57BL/6N were selected to assess the blood and urine indicators. The results showed that the levels of creatinine (CREA) and urine protein in the urine, as well as blood urea nitrogen (UREA) and creatinine (CREA), did not show significant differences compared to wild mice.
-
Analysis of kidney tissue sections
-
Analysis of kidney tissue sections: Four 48-week-old male B-hCD89 mice(H/H) and C57BL/6N were selected for kidney tissue section immunohistochemical staining analysis. The results showed IgA and C3 staining showed no significant differences between B-hCD89 mice(H/H) and C57BL/6N.
-
References
-
1.Mkaddem S B, Rossato E, Heming N, et al. Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives[J]. Autoimmunity reviews, 2013, 12(6): 666-669.,
